Entrepreneurship Articles
-
2026 Nucleate Boston Activator Cohort Interview: Anna Kazatskaya — Fervid Therapeutics, previously Antozero
6/10/2026
Anna Kazatskaya, CEO of Fervid Therapeutics is developing a novel peptide to treat pediatric epilepsy by increasing inhibitory synapses, backed by mouse data and a planned $2M pre-seed raise.
-
Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius Tx
6/5/2026
DDO interviewed Winston Haynes, VP, computational sciences and engineering, LabGenius Tx, on their T-cell engagers platform, including its lead candidate LGTX-101, a Nectin-4 CD3 molecule showing strong preclinical efficacy.
-
Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 Cohort
6/3/2026
Nucleate Boston’s 2026 Activator shows how mentorship, structure, and community can help promising young scientists become credible biotech founders.
-
Unfolding Protein & Antibody Discovery At PEGS 2026
5/19/2026
Our editorial team covers the 2026 Protein & Antibody Engineering Summit (PEGS) in Boston -- A working map of where biologics R&D is headed.
-
The Next Frontier In Women's Cancer Care: Combining Cell Therapy With Immuno-Oncology
5/19/2026
The convergence of engineered cell therapies and immuno-oncology represents a significant step forward in the quest to improve outcomes for ovarian cancer patients.
-
If AI Can't Read Your Science, Investors Won't Either
4/17/2026
As investors deploy AI to screen thousands of deals at once, life sciences founders who keep their story locked behind NDAs risk never making it past the first automated filter.
-
Execution Debt In Early Drug Discovery: The Hidden Risk That Undermines Promising Biology
3/10/2026
Understanding how execution debt forms, how it compounds, and how to prevent it is central to building durable discovery programs.
-
Thoughtful Supply Strategy Is No Longer Optional In Drug Development
2/16/2026
In drug discovery and development, supply chain decisions are often treated as a downstream concern. In reality, supply strategy is a development decision from the very beginning.
-
Annual Reflections And Predictions From The Editors' Roundtable
1/6/2026
Understanding the full scope of the life science industry has never been more critical. Ray Dogum, Chief Editor of Drug Discovery Online, joins the Life Science Connect Editors’ Roundtable on a special episode of Better Biopharma podcast.
-
The Unlikely Weapon Against Fentanyl: Your Immune System
12/23/2025
ARMR Sciences Inc. has developed a vaccine designed with a novel adjuvant, dmLT, to neutralize fentanyl in the bloodstream before it reaches the central nervous system and binds to μ-opioid receptors (MORs).